Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure
Public ClinicalTrials.gov record NCT00624065. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
COR111096, A Randomized, Double-Blind, Active-Controlled, Parallel Group, Multicenter Study Comparing the Proportion of Subjects With Stage 1 or 2 Essential Hypertension Who Achieve Target Blood Pressure While Receiving Either Carvedilol CR + Lisinopril or Lisinopril Monotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Randomized, double-blind, parallel group, multicenter study of subjects with Stage 1 or 2 essential hypertension who are not at target blood pressure (\<140/90mmHg) at Baseline. Subjects will be randomized to receive either carvedilol CR + lisinopril or lisinopril + placebo. Subjects will be uptitrated over a 6 week period until target blood pressure (\<140/90mmHg) is met. The primary objective of the study is to compare the proportion of subjects who achieve target blood pressure after 6 weeks of treatment.
Study identification
- NCT ID
- NCT00624065
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 348 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2008 (Type not available)
- Primary completion
- Aug 2008 (Actual)
- Completion
- Aug 2008 (Actual)
- Last update posted
- Dec 28, 2016
2008
United States locations
- U.S. sites
- 76
- U.S. states
- 28
- U.S. cities
- 69
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Mobile | Alabama | 36617 | — |
| GSK Investigational Site | Chandler | Arizona | 77030 | — |
| GSK Investigational Site | Glendale | Arizona | 85308 | — |
| GSK Investigational Site | Goodyear | Arizona | 85395 | — |
| GSK Investigational Site | Litchifield Park/Arizona | Arizona | 85340 | — |
| GSK Investigational Site | Phoenix | Arizona | 85032 | — |
| GSK Investigational Site | Tucson | Arizona | 85745 | — |
| GSK Investigational Site | Anaheim | California | 92801 | — |
| GSK Investigational Site | Beuna Park | California | 90620 | — |
| GSK Investigational Site | Fountain Valley | California | 92708 | — |
| GSK Investigational Site | Poway | California | 92064 | — |
| GSK Investigational Site | San Ramon | California | 94583 | — |
| GSK Investigational Site | Tustin | California | 92780 | — |
| GSK Investigational Site | Vista | California | 92081 | — |
| GSK Investigational Site | Coral Gables | Florida | 33134 | — |
| GSK Investigational Site | DeLand | Florida | 32720 | — |
| GSK Investigational Site | Fort Lauderdale | Florida | 33308 | — |
| GSK Investigational Site | Hollywood | Florida | 33023 | — |
| GSK Investigational Site | Miami | Florida | 33156 | — |
| GSK Investigational Site | Pembroke Pines | Florida | 33024 | — |
| GSK Investigational Site | Tamarac | Florida | 33321 | — |
| GSK Investigational Site | West Palm Beach | Florida | 33409 | — |
| GSK Investigational Site | Atlanta | Georgia | 30342 | — |
| GSK Investigational Site | Savannah | Georgia | 31406 | — |
| GSK Investigational Site | Nampa | Idaho | 83686 | — |
| GSK Investigational Site | Aurora | Illinois | 60504 | — |
| GSK Investigational Site | Chicago | Illinois | 60607 | — |
| GSK Investigational Site | Gillespie | Illinois | 62033 | — |
| GSK Investigational Site | Elkhart | Indiana | 46514 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46250 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46260 | — |
| GSK Investigational Site | Wichita | Kansas | 67205 | — |
| GSK Investigational Site | Wichita | Kansas | 67207 | — |
| GSK Investigational Site | Paducah | Kentucky | 42003 | — |
| GSK Investigational Site | Slidell | Louisiana | 70458 | — |
| GSK Investigational Site | Columbia | Maryland | 21045 | — |
| GSK Investigational Site | Butte | Montana | 59701 | — |
| GSK Investigational Site | Omaha | Nebraska | 68134 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89016 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89119 | — |
| GSK Investigational Site | Albuquerque | New Mexico | 87102 | — |
| GSK Investigational Site | Buffalo | New York | 14209 | — |
| GSK Investigational Site | Buffalo | New York | 14215 | — |
| GSK Investigational Site | East Syracuse | New York | 13057 | — |
| GSK Investigational Site | New York | New York | 10075 | — |
| GSK Investigational Site | Westfield | New York | 14787 | — |
| GSK Investigational Site | Raleigh | North Carolina | 27609 | — |
| GSK Investigational Site | Fargo | North Dakota | 58103 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45219 | — |
| GSK Investigational Site | Corvallis | Oregon | 97330 | — |
| GSK Investigational Site | Altoona | Pennsylvania | 16602 | — |
| GSK Investigational Site | Havertown | Pennsylvania | 19083 | — |
| GSK Investigational Site | Jersey Shore | Pennsylvania | 17740 | — |
| GSK Investigational Site | Lansdale | Pennsylvania | 19446 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19154 | — |
| GSK Investigational Site | Columbia | South Carolina | 29201 | — |
| GSK Investigational Site | Columbia | South Carolina | 29204 | — |
| GSK Investigational Site | Manning | South Carolina | 29102 | — |
| GSK Investigational Site | Johnson City | Tennessee | 37601 | — |
| GSK Investigational Site | Austin | Texas | 78705 | — |
| GSK Investigational Site | Georgetown | Texas | 78626 | — |
| GSK Investigational Site | Grand Prairie | Texas | 75052 | — |
| GSK Investigational Site | Houston | Texas | 77081 | — |
| GSK Investigational Site | San Antonio | Texas | 78224 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | Sugar Land | Texas | 77479 | — |
| GSK Investigational Site | Draper | Utah | 84020 | — |
| GSK Investigational Site | Magna | Utah | 84044 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84109 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84121 | — |
| GSK Investigational Site | Sandy City | Utah | 84094 | — |
| GSK Investigational Site | Bellingham/Washington | Washington | 98226 | — |
| GSK Investigational Site | Gig Harbor | Washington | 98335 | — |
| GSK Investigational Site | Olympia | Washington | 98502-8151 | — |
| GSK Investigational Site | Tacoma | Washington | 98405 | — |
| GSK Investigational Site | Beloit | Wisconsin | 53511 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00624065, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 28, 2016 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00624065 live on ClinicalTrials.gov.